Login to your account

Username *
Password *
Remember Me
Bibliographie

Bibliographie (2530)

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

vendredi, 14 janvier 2022 11:20 Écrit par

  Fluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario Related: Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence. RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19. [Preprint] RCT: Fluvoxamine reduced the risk for ER visits and […]

The post Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know. appeared first on Links Medicus.

Cohort Study: Patients who achieved weight loss through bariatric surgery may have lower risk for severe Covid-19 compared to patients who did not have surgical intervention for their obesity.

vendredi, 14 janvier 2022 09:36 Écrit par

Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 Infection – JAMA Surgery Commentaries: Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery? – JAMA Surgery Can weight loss help protect against Covid-19? – CNN  

The post Cohort Study: Patients who achieved weight loss through bariatric surgery may have lower risk for severe Covid-19 compared to patients who did not have surgical intervention for their obesity. appeared first on Links Medicus.

Perspective: Omicron is forcing us to rethink mild COVID.

vendredi, 14 janvier 2022 09:36 Écrit par

Omicron Is Forcing Us to Rethink Mild COVID – The Atlantic  

The post Perspective: Omicron is forcing us to rethink mild COVID. appeared first on Links Medicus.

RCT: Colchicine did not significantly reduce the need for intubation or 28-day mortality in patients hospitalized with Covid-19.

vendredi, 14 janvier 2022 09:36 Écrit par

Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial – JAMA Network Open Related: M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death. RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of […]

The post RCT: Colchicine did not significantly reduce the need for intubation or 28-day mortality in patients hospitalized with Covid-19. appeared first on Links Medicus.

‘Killer’ immune cells still recognize Omicron variant.

jeudi, 13 janvier 2022 10:13 Écrit par

‘Killer’ immune cells still recognize Omicron variant – Nature See also: T-cells: the superheroes in the battle against omicron – The Conversation  

The post ‘Killer’ immune cells still recognize Omicron variant. appeared first on Links Medicus.

Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.

jeudi, 13 janvier 2022 10:13 Écrit par

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases Invited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19  

The post Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized. appeared first on Links Medicus.

A clinical case definition of post-COVID-19 condition by a Delphi consensus.

jeudi, 13 janvier 2022 10:13 Écrit par

A clinical case definition of post-COVID-19 condition by a Delphi consensus – The Lancet Infectious Diseases   Commentary on Twitter New Review: A clinical case definition of post-#COVID19 condition by a Delphi consensus https://t.co/AoWBgCeMq5 pic.twitter.com/kAW1YY6kgr — The Lancet Infectious Diseases (@TheLancetInfDis) December 22, 2021  

The post A clinical case definition of post-COVID-19 condition by a Delphi consensus. appeared first on Links Medicus.

RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.

jeudi, 13 janvier 2022 10:13 Écrit par

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients – New England Journal of Medicine Editorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right? Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress   Commentary on Twitter Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course […]

The post RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19. appeared first on Links Medicus.